Fetal Dose Evaluation During Breast Cancer Radiotherapy

Author(s):  
Christos Antypas ◽  
Panagiotis Sandilos ◽  
John Kouvaris ◽  
Ersi Balafouta ◽  
Eleftheria Karinou ◽  
...  
Life ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 84
Author(s):  
Pattarakan Suwanbut ◽  
Thiansin Liamsuwan ◽  
Danupon Nantajit ◽  
Wilai Masa-nga ◽  
Chirapha Tannanonta

Decision for radiotherapy during the first trimester of pregnancy may occur, as patients may not realize their pregnancy at the very early stage. Since radiation dose can affect fetal development, the aim of this study was to evaluate fetal dose and associated deterministic effects and risks to the fetus from breast cancer radiotherapy of an 8-week pregnant patient. PHITS (Particle and Heavy Ion Transport code System) Monte Carlo simulation and the J-45 computational pregnancy phantom were used to simulate breast cancer radiotherapy from a 6 MV TrueBeam linear accelerator using the three dimensional-conformal radiotherapy (3D-CRT) technique with a prescribed dose to the planning target volume (PTV) of 50 Gy. Once the fetal dose was evaluated, the occurrence of the deterministic effects and risks for developing stochastic effects in the fetus were assessed using the recommendations of NCRP Report No. 174, AAPM Report No. 50, and ICRP Publication 84. The fetal dose was evaluated to be 3.37 ± 2.66 mGy, suggesting that the fetus was expected to have no additional deterministic effects, while the risks for developing cancer and malfunctions were similar to that expected from exposure to background radiation. The comparison with the other studies showed that accurate consideration of fetal position and size was important for dose determination in the fetus, especially at the early pregnancy stage when the fetus is very small.


2016 ◽  
Vol 119 ◽  
pp. S795-S796
Author(s):  
A. Fozza ◽  
L. Berta ◽  
S. Aimonetto ◽  
F. Migliaccio ◽  
A. Peruzzo Cornetto ◽  
...  

2020 ◽  
Vol 152 ◽  
pp. S795-S796
Author(s):  
D. Hernandez ◽  
M.S. Talaya ◽  
C. Anson ◽  
P. Castro ◽  
M. Roch ◽  
...  

2020 ◽  
Vol 152 ◽  
pp. S77-S78
Author(s):  
M. Verhoeven ◽  
M. Sangen van der ◽  
C. Hurkmans ◽  
L. Boersma ◽  
K. Verhoeven ◽  
...  

2017 ◽  
Vol 35 (15) ◽  
pp. 1641-1649 ◽  
Author(s):  
Carolyn Taylor ◽  
Candace Correa ◽  
Frances K. Duane ◽  
Marianne C. Aznar ◽  
Stewart J. Anderson ◽  
...  

Purpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer radiotherapy versus no radiotherapy in 75 trials yielded rate ratios (RRs) for second primary cancers and cause-specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality. Smoking status was unavailable. Third, the lung or heart ERRs per Gy in the trials and the 2010 to 2015 doses were combined and applied to current smoker and nonsmoker lung cancer and cardiac mortality rates in population-based data. Results Average doses from 647 regimens published during 2010 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart. The median year of irradiation was 2010 (interquartile range [IQR], 2008 to 2011). Meta-analyses yielded lung cancer incidence ≥ 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis of 134 cancers, indicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose. For cardiac mortality, RR was 1.30 (95% CI, 1.15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths. Detailed analyses indicated 0.04 (95% CI, 0.02 to 0.06) ERR per Gy whole-heart dose. Estimated absolute risks from modern radiotherapy were as follows: lung cancer, approximately 4% for long-term continuing smokers and 0.3% for nonsmokers; and cardiac mortality, approximately 1% for smokers and 0.3% for nonsmokers. Conclusion For long-term smokers, the absolute risks of modern radiotherapy may outweigh the benefits, yet for most nonsmokers (and ex-smokers), the benefits of radiotherapy far outweigh the risks. Hence, smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy risk.


2017 ◽  
Vol 89 (1-2) ◽  
pp. 125-127
Author(s):  
Aaron Lim ◽  
Corina Preda ◽  
Jason Stone ◽  
Andreas L. Lambrianides

2015 ◽  
Vol 88 (1055) ◽  
pp. 20150414 ◽  
Author(s):  
Benoîte Méry ◽  
Alexis Vallard ◽  
Jane-Chloé Trone ◽  
Cécile Pacaut ◽  
Jean-Baptiste Guy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document